Reactive Robotics GmbH is on track
Clinical validation, market entry in Germany and further countries secured by second investment round with existing and new investors
Founded in 2015 in Munich, Reactive Robotics GmbH is a medical device start-up with the corporate objective to provide the best possible Very Early Mobilization (VEM) to intensive care patients as early as 24 hours after hospital admission, directly in the patient’s bed. Amongst experts, VEM is regarded as one of the key factors contributing to the faster recovery of patients.
Reactive Robotics is developing an intelligent therapy device that replaces burdensome manual VEM therapy with an effective, easy and time-efficient robotic solution, enabling care takers and therapists to focus their time and energy on the patients.
Therapy that is currently only possible with enormous physical efforts by care takers and therapists should – with the help of Reactive Robotics’ intelligent systems – now become the standard-of-care.
Since Reactive Robotics GmbH’s incorporation, the company has been on track. Prototype development, the establishment of a quality management system, and cooperation with business partners and suppliers is proceeding according to plan. On a regular basis, medical Key Opinion Leaders are consulted and care-taking experts are continuously involved in product development. Leading clinics are committed to supporting the clinical validation of the solution, and business development will be systematically established.
To keep up the pace in development and go-to-market, the existing investor consortium consisting of the lead investor MTIP MedTech Innovation Partners AG, High-Tech Gründerfonds, Bayern Kapital and TQ-Group, was extended by an additional lead investor: Dr. Doll Holding GmbH.
A seven-digit investment amount should enable Reactive Robotics to achieve the ambitious time plan and to accelerate the international market entry.
About Reactive Robotics GmbH
Reactive Robotics was founded in Munich, Germany, in April 2015 with the corporate objective to
enable intensive care personnel to deliver the best possible Very Early Mobilization to intensive care
patients. The team around the founder, Dr. Alexander Koenig, established TQ-Group, one of the
leading Technology companies with broad robotics know-how, as its partner in July 2015. In May 2016,
the company closed a series-A investment together with MTIP, High-Tech Gründerfonds, Bayern
Kapital and TQ-Group.
About Dr. Doll Holding GmbH
Dr. Doll Holding GmbH, under the management of Dr. Theo Doll, holds shares in companies from the
field of plastics technology (the Söhner Kunststofftechnik GmbH) and automation and robotics (the
company Dr. Doll Engineering GmbH, IPR-Intelligente Peripherien für Roboter GmbH, Koris Vision und
Force GmbH). All companies operate very successfully and are among the market leaders in their
sector. Dr. Doll Holding GmbH invests in start-ups in the field of robotics and vision technology. Thanks
to many years of development and production experience, including in the field of medical technology,
Dr. Doll Holding GmbH can support start-ups strategically in the product development phase as well
as in the establishment of series production.
Dr. Doll Holding GmbH
Dr. Theo Doll
Tel.: +49 7138 812 200
MTIP is a Swiss-based venture capital investor specializing in the healthcare sector. Founded by entrepreneurs, our company partners with innovative start-ups in the medical device, diagnostic and digital health segments to create cost-effective and socially responsible solutions for improving patient care. Supported by seasoned investment professionals and a proprietary network of research institutions and medical facilities, we provide financial and strategic assistance from the startup through growth stages. Simply put, our goal is to empower talented entrepreneurs to develop successful and sustainable businesses with clear competitive advantages.
About High-Tech Gruenderfonds
High-Tech Gründerfonds (HTGF) is Germany’s most active seed stage investor. With about EUR 820 million under management (EUR 272 million HTGF I, EUR 304 million HTGF II, EUR 245 million HTGFIII, 1. Closing), HTGF provide financing for technology-driven companies active in a wide range of fields, including robotics, IoT and energy, Medtech and Biotech, chemicals and software. The seed financing provided is designed to enable start-ups to take their ideas through prototyping and to market launch. HTGF can provide up to EUR 3 million in total financing per company in follow-on financing rounds. Furthermore, start-ups benefit from HTGF’s team experience and expertise as well as the extensive network of investors, experts, managers and scouts. Investors in this public-private partnership include the German Federal Ministry of Economics and Energy, the KfW, Fraunhofer-Gesellschaft e.V. and numerous strategic corporate investors, including ALTANA, BASF, B.Braun, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Drillisch AG, EVONIK, Haniel, Hettich, Knauf, Körber, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik and WACKER.
High-Tech Gründerfonds Management GmbH
Tel.: +49 228 823001-06
Fax: +49 228 823000-50